All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

MRKMerck Sharp & Dohme LLC
5Calm
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Running, no new patientsPhase 1/2220 patientsMain results: Jan 15, 2029
BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
10Calm
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Signing up patientsPhase 3440 patientsMain results: Dec 30, 2027
MRKMerck Sharp & Dohme LLC
5Calm
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Signing up patientsPhase 3851 patientsMain results: Jan 12, 2029
MRKMerck Sharp & Dohme LLC
5Calm
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
FinishedPhase 2100 patientsMain results: Oct 31, 2025
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Signing up patientsPhase 1/2280 patientsMain results: Jul 1, 2030
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Signing up patientsPhase 1/2220 patientsMain results: Oct 16, 2029
VRTXVertex Pharmaceuticals Incorporated
0Calm
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Running, no new patientsPhase 234 patientsMain results: Mar 2, 2029
ELVNEnliven Therapeutics
0Calm
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
Not started yetPhase 3450 patientsMain results: Dec 31, 2028
ABBVAbbVie
1Calm
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Signing up patientsPhase 3768 patientsMain results: Dec 2028
AZNAstraZeneca
0Calm
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Signing up patientsPhase 31,160 patientsMain results: Jul 1, 2030
CTMXCytomX Therapeutics
0Calm
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
Not started yetPhase 1/2368 patientsMain results: Feb 2029
BNTXBioNTech SE
0Calm
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Signing up patientsPhase 275 patientsMain results: Jan 2028
BNTXBioNTech SE
0Calm
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Running, no new patientsPhase 2/3358 patientsMain results: Apr 2029
MRKMerck Sharp & Dohme LLC
5Calm
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Signing up patientsPhase 1/2270 patientsMain results: Feb 8, 2028
AZNAstraZeneca
0Calm
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Running, no new patientsPhase 1/255 patientsMain results: Jun 30, 2027
PGENPrecigen, Inc
2Calm
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Not started yetPhase 315 patientsMain results: Jan 2029
CGEMCullinan Therapeutics Inc.
0Calm
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Signing up patientsPhase 1/2275 patientsMain results: Dec 30, 2029
AZNAstraZeneca
0Calm
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Signing up patientsPhase 1/2408 patientsMain results: May 20, 2030
REGNRegeneron Pharmaceuticals
15Calm
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Running, no new patientsPhase 3288 patientsMain results: Jul 8, 2025
PFEPfizer
0Calm
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Signing up patientsPhase 1/2430 patientsMain results: Oct 7, 2029
AZNAstraZeneca
0Calm
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Signing up patientsPhase 1/2152 patientsMain results: Feb 23, 2029
TAKTakeda
5Calm
A Study of TAK-505 in Adults With Solid Tumors
Signing up patientsPhase 1/2151 patientsMain results: Aug 18, 2030
GILDKite, A Gilead Company
1Calm
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Running, no new patientsPhase 1/2247 patientsMain results: Feb 2030
AZNAstraZeneca
0Calm
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Signing up patientsPhase 260 patientsMain results: May 30, 2029
EXELExelixis
2Calm
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Signing up patientsPhase 2100 patientsMain results: Feb 29, 2028